HCV Infection Clinical Trial
Official title:
Role OF OCT-A TO Detect Possible Retinal Vascular Complications of Sofosbuvir (Sovaldi) in Patients With Hepatitis C Virus Infection
The purpose of this study is to prospectively evaluate the value of Optical coherence tomography angiography (OCT-A) for the of detection of suspected retinal complications With Sofosbuvir (Sovaldi) in Patients With Hepatitis C Virus Infection
During 3 months duration ( the treatment course duration) , Optical coherence tomography
angiography (OCT-A) will be performed to 30 eyes of 30 patients with a documented diagnosis
of chronic hepatitis C before and after receiving dual-therapy planning (Daclatasvir −
Sofosbuvir (Sovaldi)) , normal renal functions And Rheumatoid factor tests , will undergo a
comprehensive ophthalmic examination including:
- Manifest refraction
- Corrected distance visual acuity
- Anterior segment examination using slit lamp and tear film breakup time test
- Fundus examination
Recent Optical coherence tomography angiography (OCT-A) will be performed to all patients
before Treatment Administration.
Examination will be performed using "Optovue AngioVue®" "Optovue, Inc., Fremont, CA", which
uses split-spectrum amplitude-decorrelation angiography algorithm, which minimizes motion
noise. This system also allows quantitative analysis, since it provides numerical data about
flow area and flow density maps.
The patient will be examined before and after finishing the treatment course
* Optical coherence tomography angiography (OCT-A) image acquisition OCT-A will be done for
all patients who are instructed to focus on a fixation target. OCTA images are obtained using
the "RTVue XR Avanti (AngioVue; Optovue Inc, Fremont, California, USA)" machine and the
incorporated "AngioVue OCT-A" system. Algorithm used is Split-Spectrum Amplitude
Decorrelation Algorithm (SSADA). The scans which will be included in the study are of high
signal strength more than 0.7 and they will be carefully inspected for motion artifacts.
Automatic segmentation of intraretinal layers will be done using the automated software of
the machine (version 2016.2.0; Optovue Inc). Angio-retina scan sizes in this study will be 6
X 6 mm for all eyes. Assessment of the macular vessel density will be done for superficial
vascular layer, capillary plexus, deep capillary plexus and all retinal plexuses). Assessment
of the foveal avascular zone on both superficial vascular layer (SVL) and deep capillary
plexuses (DCP); including its size, perimeter and circularity (regularity) index. Circularity
index is a measure of compactness of a shape relative to a circle. The circularity index of a
circle is 1.0. Thus, a ratio closer to 0 indicates an irregular shape, and that closer to 1.0
indicates a circular shape.
All results will be in numerical values (percentage) to compare retinal vascularity before
and after using the drug. Best corrected visual acuity (in values from o.o5 to 1.0) , dryness
(in seconds) will be also measured before and after drug administration and it will be
compared .
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03674125 -
Evaluation of Safety, Tolerability, and Immunogenicity Study of GLS-6150 in Healthy Volunteers and in Persons Previously Treated for Hepatitis C Virus Infection
|
Phase 1 | |
Completed |
NCT00978497 -
Safety, Tolerability, and Antiviral Activity of ANA598 Administered in Combination With Pegylated Interferon and Ribavirin for the Treatment of Genotype-1 Chronic HCV Infection
|
Phase 2 | |
Completed |
NCT00170131 -
MMF Influence on HCV Viral Evolution After Liver Transplantation
|
Phase 4 | |
Completed |
NCT04008927 -
A Community-based Intervention Among Active Drug Users in Montpellier
|
N/A | |
Active, not recruiting |
NCT04044586 -
HIV and HCV Infections in 2 Communes From the Battambang Province, Cambodia: Prevalence Rates, Viral Strains, and Unsafe Injection Practices (12352 ANRS ROK INVEST)
|
||
Completed |
NCT01958281 -
Sofosbuvir Plus Ribavirin, or Ledipasvir/Sofosbuvir in Adults With HCV Infection and Renal Insufficiency
|
Phase 2 | |
Completed |
NCT02533427 -
Study to Evaluate Effect of Sofosbuvir/Velpatasvir/GS-9857 Fixed-Dose Combination on the Pharmacokinetics of a Representative Hormonal Contraceptive Medication, Norgestimate/Ethinyl Estradiol
|
Phase 1 | |
Completed |
NCT02783976 -
Sovaldi-based Regimens in Patients in Mexico With Chronic Hepatitis C Virus Infection in Clinical Practice
|
||
Withdrawn |
NCT04309734 -
Study of AT-777 in Healthy Subjects and AT-777 in Combination With AT-527 in HCV-Infected Subjects
|
Phase 1/Phase 2 | |
Completed |
NCT01965535 -
Efficacy and Safety of Sofosbuvir/Ledipasvir Fixed-Dose Combination ± Ribavirin in Cirrhotic Subjects With Chronic Genotype 1 HCV Infection
|
Phase 2 | |
Completed |
NCT00743795 -
Safety, Tolerability, and Antiviral Activity of 24 or 48 Weeks of GS-9190 in Combination With Peginterferon Alfa 2a and Ribavirin for the Treatment of Genotype-1 Chronic HCV Infection
|
Phase 2 | |
Completed |
NCT00768690 -
A Study in Healthy Adult Subjects to Evaluate the Safety, Tolerability, and Pharmacokinetics of Multiple Doses of ABT-333
|
Phase 1 | |
Withdrawn |
NCT04235049 -
Elimination of HCV Through Linkage and In Prison Treatment of Incarcerated Populations (ECLIPSE)
|
Phase 4 | |
Terminated |
NCT00401947 -
A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of ACH-0137171 in Participants With Chronic Hepatitis C Infection
|
Phase 2 | |
Completed |
NCT00959699 -
A Phase 2b, Safety and Efficacy Study of Boceprevir in Patients Coinfected With HIV and Hepatitis C (P05411 AM4)
|
Phase 2 | |
Completed |
NCT00623649 -
Safety,Tolerability and Pharmacokinetics of Multiple Ascending Doses of VCH 916 in Subjects With Chronic Hep C Infection
|
Phase 1 | |
Completed |
NCT00221624 -
Peginterferon Alfa-2a Plus Ribavirin Plus Amantadine for the Treatment of Hepatitis C Infected Patients
|
Phase 3 | |
Completed |
NCT04134767 -
Kentucky Communities and Researchers Engaging to Halt the Opioid Epidemic (CARE2HOPE)
|
N/A | |
Completed |
NCT02402452 -
Pharmacokinetics of Voxilaprevir in Adults With Normal Renal Function and Severe Renal Impairment
|
Phase 1 | |
Terminated |
NCT00874796 -
Efficacy and Safety Study of GS-9450 Treatment for 6 Months in Patients With Chronic Hepatitis C Virus Infection
|
Phase 2 |